查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997149

免疫腫瘤臨床試驗市場：依治療方法、試驗階段、適應症、試驗類型、申辦者及病患入組分類－2026-2032年全球市場預測

Immuno-oncology Clinical Trials Market by Therapy Type, Trial Phase, Indication, Trial Type, Sponsor Type, Patient Enrollment - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年免疫腫瘤臨床試驗市值為 74 億美元，預計到 2026 年將成長至 83.2 億美元，複合年成長率為 14.81%，到 2032 年將達到 194.7 億美元。

主要市場統計數據
基準年 2025 74億美元
預計年份：2026年 83.2億美元
預測年份 2032 194.7億美元
複合年成長率 (%) 14.81%

對不斷發展的免疫腫瘤臨床試驗環境進行簡要概述，重點關注轉化研究的成熟、多方合作和運作挑戰。

在生物學知識、先進製造平台和日益精細的試驗設計融合的推動下，免疫腫瘤學臨床試驗正進入加速創新階段。過去十年，免疫調節療法已從早期概念驗證研究發展成為複雜的、多組、以生物標記為重點的試驗，這些試驗不僅關注臨床療效，還整合了轉化終點。這一趨勢反映了該領域的日益成熟，闡明作用機制、選擇合適的患者、制定聯合治療策略以及相關的基礎治療方法，都決定了計畫的可行性。

科學融合、製造創新和監管適應性如何重塑免疫腫瘤學的臨床試驗策略和治療途徑。

在科學突破、技術進步和不斷變化的監管預期推動下，腫瘤免疫學領域正經歷著一場變革。從機制上看，該領域正從查核點抑制劑）轉向整合療法，將過繼性細胞療法、疫苗、細胞激素調節和靶向溶瘤藥物相結合，以克服抗藥性並擴大有效人群。這種轉變得益於對腫瘤微環境異質性、克隆動力學和免疫逃脫機制的更深入理解，這些理解共同促成了合理的聯合治療策略和更精準的患者選擇。

評估美國於 2025 年實施的關稅措施對臨床試驗物流、製造和跨境合作研究的營運和策略外溢效應。

美國2025年推出的定向關稅政策，為依賴全球採購的材料、專用設備和跨境臨床合作進行免疫腫瘤學試驗的臨床試驗贊助者帶來了重大的營運挑戰。實驗室試劑、輔助設備和某些生物製藥成分的進口關稅不斷提高，正逐步增加複雜臨床試驗（尤其是依賴海外生產的試劑和一次性耗材的細胞療法）的每位患者的成本。除了直接的成本影響外，關稅還影響採購計畫和庫存策略，促使申辦方和臨床試驗中心在其供應鏈中預留更充足的緩衝空間，以降低供應鏈中斷的風險。

綜合細分分析揭示了治療方法類型、臨床實驗生命週期、臨床適應症、申辦者概況和策略影響方面的差異。

精細化的細分觀點能夠深入洞察治療潛力、營運準備和臨床檢驗三者相契合的領域。根據治療方法類型，該領域涵蓋細胞療法、癌症疫苗、查核點抑制劑、細胞激素療法和溶瘤病毒。細胞療法再細分為CAR-T細胞療法、NK細胞療法和TCR-T細胞療法；癌症疫苗包括樹突細胞疫苗、DNA疫苗和胜肽疫苗。查核點抑制劑根據其標靶進行區分：CTLA-4、PD-1和PD-L1；細胞激素療法包括干擾素療法和白細胞介素-2。干擾素療法再細分為干擾素-α和干擾素-γ。這種治療方法分類系統突顯了技術風險和生產複雜性，顯示基於平台的細胞療法需要廣泛的供應鏈協調，而胜肽類疫苗和特定的查核點策略則更容易實現規模化生產。

透過評估美洲、歐洲、中東和非洲以及亞太地區的地理優勢和營運權衡，最佳化臨床實驗順序和臨床實驗選擇。

由於每個地區都具有其獨特的科學、監管和物流特徵，這些特徵會影響專案的可行性和證據獲取速度，因此區域趨勢持續影響臨床試驗策略和營運設計。在美洲，緊密的學術醫療中心網路、成熟的法規結構和完善的契約製造有利於臨床試驗生態系統的發展，這些因素共同支持著複雜的細胞和基因項目，並促進針對特定適應症的快速受試者招募。另一方面，在選擇臨床實驗中心時，必須考慮支付方預期和核准後推廣路徑的區域差異，以確保後期證據與商業化計畫相符。

檢驗了以平台為中心的創新者、中型生物技術公司、學術聯盟和服務合作夥伴的策略行為，並確定了夥伴關係模式和營運優勢。

免疫腫瘤學試驗中的企業行為反映了平台導向創新者和適應症導向開發者之間的兩極化，從而在生態系統中形成了互補的角色。大型製藥企業往往優先考慮後期檢驗、全球監管策略和商業化準備，並在註冊試驗和全球供應鏈基礎設施方面投入大量資金。中型生物技術公司通常專注於首次人體概念驗證（PoC）和轉化檢驗，利用適應性設計和生物標記篩選隊列快速迭代作用機制和檢驗。同時，學術機構和聯盟提供基礎科學、研究者主導的臨床試驗以及早期訊號產生所需的特殊檢測方法和患者群體。

為高階主管提供切實可行的措施，以將科學重點與製造韌性、適應性測試設計、轉化嚴謹性和策略夥伴關係相結合。

產業領導者必須採取實際措施，將科學研究機會轉化為營運穩健的項目，從而高效能惠及病患並產生永續的證據。首先，應優先精簡產品組合，重點在於作用機制的清晰度和營運可行性，並將資源集中於生物證據、可生產性和可行監管途徑均符合要求的資產。其次，應投資於生產韌性，例如認證多家關鍵試劑供應商、擴大國內高敏感性原料的生產能力，以及在合約和預算中納入緊急時應對計畫。這些措施將有助於降低供應鏈中斷帶來的風險，並確保可預測的檢測計畫。

對用於建構臨床、營運和監管方面可操作見解的資料來源、分析方法、專家檢驗程序和限制進行透明說明。

本報告整合了臨床試驗註冊數據、同行評審的轉化研究、監管指導文件以及對臨床管理人員、生產專家和監管從業人員的直接訪談，從而構建了免疫腫瘤學臨床試驗的整體情況。資料整合著重於試驗層面的屬性，例如治療方法、試驗階段、適應症、申辦者類型、試驗設計特徵和研究中心地理分佈，並輔以關於生產實踐、供應鏈限制和夥伴關係結構的定性資訊。分析方法包括橫斷面比較以識別營運差異，對展示最佳實踐的代表性項目進行案例研究，以及情境規劃以評估政策變化和供應鏈中斷的影響。

一項權威的綜合分析重點闡述了科學、製造和監管策略如何共同作用，將轉化潛力轉化為永續的臨床和患者影響。

總之，免疫腫瘤學臨床試驗生態系統的特點是科學創新、營運精細化和策略合作之間的動態互動。儘管治療方法的進步為治療血液腫瘤和固態腫瘤開闢了新的途徑，但成功的轉化研究需要技術複雜性和生產能力、監管前瞻性以及與以患者為中心的試驗設計相一致。關稅政策和供應鏈壓力日益凸顯了本地生產和穩健的供應商策略的重要性，而區域優勢則決定了專案從概念驗證（PoC）開始，到最終獲得註冊核准的檢驗的開展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：免疫腫瘤臨床試驗市場（依治療方法）

  • 細胞療法
    • CAR-T
    • NK細胞療法
    • TCR-T
  • 癌症疫苗
    • 樹突細胞疫苗
    • DNA疫苗
    • 胜肽疫苗
  • 查核點抑制劑
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 細胞激素療法
    • 干擾素療法
      • α干擾素
      • 干擾素γ
    • 白細胞介素-2
  • 溶瘤病毒

第9章：依試驗階段分類的免疫腫瘤臨床試驗市場

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第10章：免疫腫瘤臨床試驗市場：依適應症分類

  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 結腸癌
    • 肺癌
    • 惡性黑色素瘤

第11章：按試驗類型分類的免疫腫瘤臨床試驗市場

  • 干預類型
  • 觀察性研究

第12章：按申辦方分類的免疫腫瘤臨床試驗市場

  • 學術機構
  • 生技公司
  • 聯盟
  • 製藥公司

第13章：以病人入組人數分類的免疫腫瘤臨床試驗市場

  • 大規模
  • 中號
  • 小規模

第14章：免疫腫瘤臨床試驗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：免疫腫瘤臨床試驗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：免疫腫瘤臨床試驗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國免疫腫瘤臨床試驗市場

第18章：中國免疫腫瘤臨床試驗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Charles River Laboratory
  • Clinipace Company
  • Eli Lilly and Company
  • ICON PLC
  • IQVIA
  • Novo Nordisk A/S
  • PAREXEL International Corporation
  • Pfizer Inc.
  • PRA Health Sciences
  • SGS SA
  • Syneos Health
  • Wuxi AppTec Inc.
Product Code: MRR-035590447475

The Immuno-oncology Clinical Trials Market was valued at USD 7.40 billion in 2025 and is projected to grow to USD 8.32 billion in 2026, with a CAGR of 14.81%, reaching USD 19.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.40 billion
Estimated Year [2026] USD 8.32 billion
Forecast Year [2032] USD 19.47 billion
CAGR (%) 14.81%

A concise synthesis of the evolving immuno-oncology trial environment highlighting translational maturation, multi-stakeholder collaboration, and operational imperatives for advancement

The immuno-oncology clinical trial landscape has entered a phase of accelerated innovation driven by converging biological insights, advanced manufacturing platforms, and increasingly sophisticated trial designs. Over the past decade, immune-modulating modalities have evolved from early proof-of-concept studies to complex, multi-arm, biomarker-enriched trials that integrate translational endpoints alongside clinical efficacy. This trend reflects a maturing field where mechanistic clarity, patient selection, and combination strategies determine program viability as much as the underlying therapeutic modality.

Translational science now underpins trial hypotheses more consistently, with companion diagnostics and deep immune monitoring embedded in protocols to enable adaptive decision-making. At the same time, sponsors are balancing the logistical and regulatory demands of cell- and gene-based interventions with the imperative to reduce time-to-clinic and scale manufacturing. As a result, cross-sector collaboration among academic centers, biotechnology firms, and large pharmaceutical organizations has intensified, with trial networks and consortiums forming to share expertise, standardize assays, and accelerate enrollment for rare indications.

Consequently, decision-makers must synthesize biological rationale, operational feasibility, and regulatory pathways to prioritize assets and trial designs. Strategic clarity around patient segmentation, end-point selection, and manufacturing resilience will be a differentiator for programs that advance beyond early-stage promise to durable clinical impact

How scientific convergence, manufacturing innovation, and regulatory adaptability are reshaping clinical trial strategies and therapeutic pathways in immuno-oncology

The immuno-oncology landscape is undergoing transformative shifts driven by scientific breakthroughs, technology diffusion, and evolving regulatory expectations. Mechanistically, the field is moving beyond single-agent checkpoint blockade toward integrated approaches that combine adoptive cell therapies, vaccines, cytokine modulation, and targeted oncolytics to overcome resistance and broaden responder populations. This transition is supported by enhanced understanding of tumor microenvironment heterogeneity, clonal dynamics, and immune evasion mechanisms, which collectively enable rational combination strategies and more precise patient selection.

Technological advances have also altered operational realities. Improvements in cell manufacturing, cryopreservation, and decentralized production modalities are reducing lead times and expanding the feasible geography for complex trials. Simultaneously, digital health tools for remote monitoring, decentralization of site responsibilities, and real-world data integration are increasing trial flexibility and patient retention. Regulatory pathways are adapting incrementally, with agencies signaling openness to adaptive designs, basket and umbrella studies, and conditional approval frameworks based on robust surrogate endpoints.

Financially, investment focus is shifting toward later-stage de-risked assets and platform technologies that can generate multiple clinical programs. As a result, strategic partnerships and platform licensing are becoming more common, enabling smaller innovators to access development capacity while larger sponsors diversify pipelines. The cumulative effect is a more intricate, collaborative, and efficient ecosystem, where scientific innovation and operational innovation co-evolve to expand therapeutic possibilities

Assessing the operational and strategic ripple effects of United States tariff measures introduced in 2025 on clinical trial logistics, manufacturing, and cross-border collaborations

The introduction of targeted tariff policies in the United States in 2025 has introduced a material operational consideration for sponsors conducting immuno-oncology trials that depend on globally sourced materials, specialized instruments, and cross-border clinical collaborations. Higher import duties on laboratory reagents, ancillary devices, and certain biologic components have incrementally increased the per-patient cost structure for complex trials, particularly for adoptive cell therapies that rely on reagents and single-use consumables often manufactured abroad. Beyond direct cost effects, tariffs influence procurement timelines and inventory strategies as sponsors and clinical sites adopt more conservative supply chain buffers to mitigate disruption risk.

In response, many organizations are accelerating localization of critical manufacturing steps and qualifying domestic suppliers for key inputs to reduce exposure to import fluctuations. This shift has implications for capital allocation, as sponsors invest in onshore contract manufacturing organizations, expand in-house process development capabilities, and renegotiate supplier contracts to include contingency clauses. As a result, trial budgets and site selection criteria are increasingly evaluated through a lens that combines clinical feasibility with supply chain resiliency.

Tariff-driven dynamics also affect collaborative models. International academic partnerships and multi-national trial networks face heightened administrative complexity in coordinating material transfers and aligning GMP specifications across jurisdictions. Consequently, sponsors are prioritizing regulatory harmonization, advanced planning for cross-border logistics, and early engagement with customs and trade specialists. While the near-term impact has been to elevate operational costs and timelines for some programs, the enforced emphasis on supply chain robustness is catalyzing long-term benefits in manufacturing redundancy and quality assurance that will inform program design and go-to-market planning going forward

Integrated segmentation analysis illuminating therapeutic modality distinctions, trial lifecycle differences, clinical indications, sponsor profiles, and enrollment scale implications for strategy

A granular segmentation lens yields actionable insight into where therapeutic promise aligns with operational readiness and clinical validation. Based on therapy type, the landscape encompasses adoptive cell therapies, cancer vaccines, checkpoint inhibitors, cytokine therapies, and oncolytic viruses, with adoptive cell therapies subdivided into CAR-T, NK cell therapy, and TCR-T while cancer vaccines include dendritic cell, DNA, and peptide approaches; checkpoint inhibitors remain differentiated by CTLA-4, PD-1, and PD-L1 targets, and cytokine efforts feature interferon therapies and interleukin-2 where interferon approaches are further specified by interferon alpha and interferon gamma. This therapeutic taxonomy clarifies technological risk and manufacturing complexity, showing that platform-based cell therapies require extensive supply chain coordination, whereas peptide vaccines and certain checkpoint strategies scale more readily.

Based on trial phase, programs span Phase I through Phase IV, with early-phase work dominated by exploratory biomarker integration and safety optimization and later-phase studies emphasizing registrational endpoints and payer-relevant outcomes. Based on indication, the portfolio splits between hematological malignancies and solid tumors; hematologic programs target leukemia, lymphoma, and myeloma while solid tumor efforts focus on breast, colorectal, lung cancers, and melanoma. This dichotomy reveals divergent patient-recruitment strategies and endpoint selection, as hematologic trials frequently rely on measurable disease markers and centralized labs, and solid tumor trials demand robust imaging cohorts and site differentiation.

Based on sponsor type, trials are sponsored by academic institutions, biotechnology companies, consortiums, and pharmaceutical companies, each bringing differing governance, operational scale, and access to patient networks. Based on trial type, the field divides into interventional and observational studies, with interventional designs driving therapeutic validation and observational cohorts generating real-world evidence. Finally, based on patient enrollment, trials range from small-scale, focused cohorts to medium and large-scale studies, a distribution that influences statistical design, site selection, and resource allocation. Together these segmentation lenses inform prioritization by aligning scientific hypotheses with executional capacity and strategic intent

Evaluating geographical strengths and operational trade-offs across the Americas, Europe Middle East & Africa, and Asia-Pacific to optimize trial sequencing and site selection

Regional dynamics continue to shape trial strategy and operational design, as each geography presents unique scientific, regulatory, and logistical attributes that influence program feasibility and speed to evidence. In the Americas, the trial ecosystem benefits from dense networks of academic medical centers, mature regulatory frameworks, and established contract manufacturing capacity, which together support complex cell- and gene-based programs and facilitate rapid cohort accrual for certain indications. Conversely, site selection decisions must account for regional variations in payer expectations and post-approval adoption pathways to ensure that late-stage evidence aligns with commercialization plans.

In Europe, Middle East & Africa, heterogeneity in regulatory processes, reimbursement pathways, and clinical infrastructure necessitates early regulatory engagement and protocol harmonization across countries. This region offers valuable opportunities for multinational enrollment in both rare hematologic indications and diverse solid tumor cohorts, but success depends on centralized data management and consistent assay standardization. Meanwhile, in the Asia-Pacific region, rising clinical research capacity, expanding biotech innovation hubs, and cost-effective manufacturing options present compelling advantages for both early-phase studies and larger, pragmatic trials. However, ethical review timelines, import-export logistics, and local manufacturing qualification must be integrated into program timelines.

Across regions, sponsors are employing hybrid trial models, leveraging decentralized elements where appropriate and aligning site responsibilities with regional strengths. Strategic regional sequencing-initiating proof-of-concept work in centers with deep translational expertise, then scaling into regions with high patient availability and manufacturing support-continues to be a dominant approach for programs aiming to optimize speed, cost, and evidentiary rigor

Examining strategic behaviors of platform-focused innovators, mid-size biotechs, academic consortia, and service partners to identify partnership models and execution strengths

Company behavior within immuno-oncology trials reflects a bifurcation between platform-oriented innovators and indication-focused developers, creating complementary roles in the ecosystem. Large pharmaceutical organizations tend to emphasize late-stage validation, global regulatory strategy, and commercialization readiness, investing heavily in registrational trials and global supply chain infrastructure. Mid-sized biotechnology companies often concentrate on first-in-human proof-of-concept and translational validation, leveraging adaptive designs and biomarker-enriched cohorts to rapidly iterate on mechanism and dose. Meanwhile, academic institutions and consortia provide foundational science, investigator-led trials, and access to specialized assays and patient populations that are critical for early signal generation.

Partnership models are increasingly sophisticated, ranging from co-development and joint governance to licensing arrangements where platform owners supply manufacturing and process expertise while partners drive clinical execution. Contract research organizations and contract manufacturing organizations play essential roles in scaling trials, particularly for cell- and gene-based modalities, where GMP compliance, chain-of-identity controls, and cold-chain logistics are paramount. Observed strategic behaviors include portfolio pruning-where companies prioritize fewer, higher-conviction programs-and platform consolidation, where single technological approaches are extended across multiple indications to capture development leverage.

Taken together, company-level insights suggest that sponsors who align clinical ambition with manufacturing capacity, regulatory strategy, and a clear partnership model tend to execute trials with greater predictability. Executives should therefore assess organizational strengths against the modality-specific demands of their pipeline and consider strategic alliances that mitigate operational risk while accelerating clinical validation

Practical, high-impact steps for executives to align scientific priorities with manufacturing resilience, adaptive trial design, translational rigor, and strategic partnerships

Industry leaders must take deliberate steps to convert scientific opportunity into operationally sound programs that reach patients efficiently and generate durable evidence. First, prioritize portfolio rationalization centered on mechanistic clarity and operational realism; focus resources on assets where biological rationale, manufacturability, and a feasible regulatory pathway align. Second, invest in manufacturing resilience by qualifying multiple suppliers for critical reagents, expanding domestic capacity for sensitive inputs, and embedding contingency planning into contracts and budgets. These measures reduce vulnerability to supply chain shocks and support predictable trial timelines.

Third, adopt flexible trial designs that integrate adaptive elements, biomarker-driven cohorts, and decentralized components where clinically appropriate. This approach accelerates learning, reduces unnecessary exposure, and improves patient access. Fourth, strengthen translational frameworks that couple protocol-design with robust immune monitoring and harmonized assays to generate interpretable mechanistic readouts that inform downstream decisions. Fifth, pursue selective partnerships: collaborate with academic centers for early translational depth, with specialized CMOs for manufacturing scale-up, and with experienced CROs for complex operational execution. Finally, ensure early payer and regulatory engagement to align evidentiary programs with reimbursement expectations and approval pathways, thereby smoothing the path from clinical proof to patient access.

By executing these imperatives in concert, leaders can reduce development risk, compress timelines, and enhance the probability that promising immuno-oncology interventions translate into meaningful clinical and commercial outcomes

Transparent description of data sources, analytical techniques, expert validation steps, and limitations used to construct actionable insights across clinical, operational, and regulatory dimensions

This report synthesizes evidence from trial registries, peer-reviewed translational studies, regulatory guidance documents, and primary consultations with clinical operations leaders, manufacturing experts, and regulatory affairs practitioners to build a comprehensive view of the immuno-oncology trial landscape. Data integration emphasized trial-level attributes such as modality, phase, indication, sponsor type, trial design features, and site geography, augmented by qualitative input on manufacturing practices, supply chain constraints, and partnership structures. Analytical methods included cross-sectional comparisons to identify operational differentiators, case-based analysis of representative programs to illustrate best practices, and scenario planning to assess the effects of policy shifts and supply chain disruptions.

Quality assurance processes included triangulation across multiple independent sources, validation of protocol-level descriptions against sponsor disclosures, and expert review to ensure clinical and operational plausibility. Where proprietary datasets were used to augment public information, findings were presented at an aggregated level to preserve confidentiality while enabling actionable insight. Limitations of the methodology are acknowledged: rapidly evolving trial outcomes, emerging regulatory guidance, and real-time supply chain changes may alter operational calculus. To mitigate these limitations, recommended usage includes periodic updates and targeted deep dives focused on specific modalities or geographies. The methodological approach supports decision-makers by linking empirical trial attributes with executable operational recommendations and strategic pathways for program advancement

A decisive synthesis highlighting how aligned scientific, manufacturing, and regulatory strategies convert translational promise into sustainable clinical and patient impact

In conclusion, the immuno-oncology clinical trial ecosystem is characterized by a dynamic interplay between scientific innovation, operational sophistication, and strategic collaboration. Therapeutic advances are unlocking new avenues to address both hematologic and solid tumor indications, but successful translation depends on aligning technical complexity with manufacturing capability, regulatory foresight, and patient-centered trial design. Tariff policies and supply chain pressures have elevated the importance of localized manufacturing and robust supplier strategies, while regional strengths shape where programs initiate proof-of-concept work and where they scale to registrational validation.

Decision-makers should act with strategic focus: concentrate on high-conviction assets where translational rationale is supported by operational feasibility, establish partnerships that fill capability gaps, and adopt flexible trial designs that accelerate learning while managing risk. By integrating translational rigor with pragmatic operational planning and regional sequencing, sponsors can increase the probability that promising immuno-oncology approaches progress from experimental validation to meaningful clinical impact. The path forward requires coordinated investment across science, manufacturing, and trial design to ensure that therapeutic innovation reaches patients efficiently and sustainably

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immuno-oncology Clinical Trials Market, by Therapy Type

  • 8.1. Adoptive Cell Therapies
    • 8.1.1. Car-T
    • 8.1.2. Nk Cell Therapy
    • 8.1.3. Tcr-T
  • 8.2. Cancer Vaccines
    • 8.2.1. Dendritic Cell Vaccines
    • 8.2.2. Dna Vaccines
    • 8.2.3. Peptide Vaccines
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. Ctla-4 Inhibitors
    • 8.3.2. Pd-1 Inhibitors
    • 8.3.3. Pd-L1 Inhibitors
  • 8.4. Cytokine Therapies
    • 8.4.1. Interferon Therapies
      • 8.4.1.1. Interferon Alpha
      • 8.4.1.2. Interferon Gamma
    • 8.4.2. Interleukin-2
  • 8.5. Oncolytic Viruses

9. Immuno-oncology Clinical Trials Market, by Trial Phase

  • 9.1. Phase I
  • 9.2. Phase Ii
  • 9.3. Phase Iii
  • 9.4. Phase Iv

10. Immuno-oncology Clinical Trials Market, by Indication

  • 10.1. Hematological Malignancies
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
    • 10.1.3. Myeloma
  • 10.2. Solid Tumors
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Melanoma

11. Immuno-oncology Clinical Trials Market, by Trial Type

  • 11.1. Interventional
  • 11.2. Observational

12. Immuno-oncology Clinical Trials Market, by Sponsor Type

  • 12.1. Academic Institutions
  • 12.2. Biotechnology Companies
  • 12.3. Consortiums
  • 12.4. Pharmaceutical Companies

13. Immuno-oncology Clinical Trials Market, by Patient Enrollment

  • 13.1. Large Scale
  • 13.2. Medium Scale
  • 13.3. Small Scale

14. Immuno-oncology Clinical Trials Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Immuno-oncology Clinical Trials Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immuno-oncology Clinical Trials Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Immuno-oncology Clinical Trials Market

18. China Immuno-oncology Clinical Trials Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Charles River Laboratory
  • 19.6. Clinipace Company
  • 19.7. Eli Lilly and Company
  • 19.8. ICON PLC
  • 19.9. IQVIA
  • 19.10. Novo Nordisk A/S
  • 19.11. PAREXEL International Corporation
  • 19.12. Pfizer Inc.
  • 19.13. PRA Health Sciences
  • 19.14. SGS SA
  • 19.15. Syneos Health
  • 19.16. Wuxi AppTec Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 263. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 266. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 267. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 268. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 269. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 270. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 273. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR T